|
|
|
|
| LEADER |
03048nam a22005055i 4500 |
| 001 |
978-3-319-22189-2 |
| 003 |
DE-He213 |
| 005 |
20151204154225.0 |
| 007 |
cr nn 008mamaa |
| 008 |
150827s2015 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319221892
|9 978-3-319-22189-2
|
| 024 |
7 |
|
|a 10.1007/978-3-319-22189-2
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC254-282
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 245 |
1 |
0 |
|a Pan-cancer Integrative Molecular Portrait Towards a New Paradigm in Precision Medicine
|h [electronic resource] /
|c edited by Christophe Le Tourneau, Maud Kamal.
|
| 250 |
|
|
|a 1st ed. 2015.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2015.
|
| 300 |
|
|
|a X, 144 p. 100 illus., 50 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
|
|a Introduction: Rationale for Precision Medicine Clinical Trials.- The Key Role of Pathology in the Context of Precision Medicine Trials -- Basis for Molecular Genetics in Cancer -- Microarrays Based Molecular Profiling to Identify Genomic Alterations -- High Throughput Technologies: DNA and RNA Sequencing Strategies and Potential -- Bioinformatics for Precision Medicine in Oncology -- Assessment of Biomarkers’ Predictive Value of Efficacy -- Designs for Evaluating Precision Medicine Trials -- Conclusions and Perspectives: Challenges for the Clinical Implementation of Precision Medicine Trials.
|
| 520 |
|
|
|a This original book provides readers with an overview of the latest developments in personalized medicine clinical trials in oncology. The topics covered range from the rationale behind this new generation of clinical trials and the latest statistical models for high-throughput molecular techniques, bioinformatics, high-throughput screening molecular techniques and the challenges entailed by implementing them in daily practice. It also covers the key role of pathology in the validation of molecular results and the complex assessment of predictive biomarkers. The different topics covered are supplemented by unique concrete examples based on the SHIVA trial. The authors are all members of the French Curie Institute, one of the world’s foremost cancer research institutions.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
0 |
|a Pathology.
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Pathology.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|
| 700 |
1 |
|
|a Le Tourneau, Christophe.
|e editor.
|
| 700 |
1 |
|
|a Kamal, Maud.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319221885
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-22189-2
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
